MOACM
CTKB icon

Mutual of America Capital Management’s Cytek Biosciences CTKB Stock Holding History

Mutual of America Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55K Buy
12,584
+16
+0.1% +$76 ﹤0.01% 1363
2025
Q4 		$63.5K Buy
12,568
+312
+3% +$1.45K ﹤0.01% 1357
2025
Q3 		$42.5K Sell
12,256
-923
-7% -$3.46K ﹤0.01% 1351
2025
Q2 		$44.8K Sell
13,179
-2,015
-13% -$6.71K ﹤0.01% 1374
2025
Q1 		$60.9K Sell
15,194
-611
-4% -$3.17K ﹤0.01% 1412
2024
Q4 		$103K Sell
15,805
-215
-1% -$1.28K ﹤0.01% 1429
2024
Q3 		$88.8K Buy
16,020
+269
+2% +$1.52K ﹤0.01% 1441
2024
Q2 		$87.9K Sell
15,751
-1,296
-8% -$7.78K ﹤0.01% 1446
2024
Q1 		$114K Sell
17,047
-272
-2% -$2.15K ﹤0.01% 1454
2023
Q4 		$158K Sell
17,319
-125
-0.7% -$787 ﹤0.01% 1424
2023
Q3 		$96.3K Buy
17,444
+1,810
+12% +$14.5K ﹤0.01% 1430
2023
Q2 		$134K Buy
+15,634
New +$140K ﹤0.01% 1446

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mutual of America Capital Management's CTKB Position: Q1 2026 in Review

Mutual of America Capital Management increased its Cytek Biosciences (CTKB) stake by 0.13% in Q1 2026, buying an estimated $76 and bringing the position to 12,584 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #1363.

Mutual of America Capital Management first reported a position in CTKB in Q2 2023 and has held it in 12 quarters since. The position peaked at $158K in Q4 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Mutual of America Capital Management held 12,584 shares of Cytek Biosciences worth $55K as of Q1 2026.
  • Mutual of America Capital Management bought 16 Cytek Biosciences shares in Q1 2026, an estimated $76.
  • Cytek Biosciences made up ﹤0.01% of Mutual of America Capital Management's portfolio in Q1 2026, its #1363 holding.
  • Mutual of America Capital Management first reported a position in Cytek Biosciences in Q2 2023 and has held it in 12 quarters since.
  • Mutual of America Capital Management's Cytek Biosciences position peaked at $158K in Q4 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Mutual of America Capital Management's 13F filing for Q1 2026, filed 7 May 2026.